Stevanato Group Publishes Third-Quarter Financial Results Call Transcript

By Public Technologies
  • Stevanato Group’s November 3, 2026, third-quarter earnings call featured CEO Franco Stevanato, CFO Marco Dal Lago and communications chief Lisa Miles.
  • Management expects low-single-digit growth in 2027 as lower GLP-1 volumes from one customer temporarily constrain growth.
  • Most affected syringe capacity has been backfilled; management expects more normalized growth in 2028 as broader biologics demand offsets the shortfall.
  • Full-year 2026 guidance remains unchanged at €1.26 billion–€1.28 billion revenue and €335 million–€345.2 million adjusted EBITDA.
  • Third-quarter revenue rose 8% to €326.1 million; non-GLP biologics revenue increased more than 30%, offsetting declining GLP-1 sales.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stevanato Group S.p.A. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-458313), on November 12, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.